Literature DB >> 34823105

Bcl-xL and IP3R interaction: Intimate relationship with an uncertain outcome.

Nikolay Popgeorgiev1, Germain Gillet2.   

Abstract

Bcl-2 family proteins are major apoptosis regulators. They control a key step in apoptosis execution referred to as the mitochondrial outer membrane permeabilization. Several Bcl-2 homologs were also reported to act at the level of the endoplasmic reticulum (ER) where they control intracellular Ca2+ trafficking. There is an increasing body of evidence that, in addition to their conventional role as MOMP regulators, several Bcl-2 family members, including Bcl-xL, are linked to Ca2+ -dependent processes, independent of cell death. Among them Bcl-xL has been proposed to promote IP3R1 channel opening and sustain mitochondrial bioenergetics. A recent article by Rosa and colleagues in Cell Death & Differentiation challenges this model and support the notion that Bcl-xL acts more as a repressor than as a sensitizer of IP3R1 opening. They suggest the existence of intrafamilial competition among the Bcl-2 family of protein with respect to their effect on IP3R Ca2+ permeability, which might be important regarding their respective non-canonical functions. In this regard, the results by Rosa and colleagues open exciting avenues regarding the biological process by which Bcl-xL affects Ca2+ trafficking through IP 3 R channels.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Bcl-2 family; Calcium trafficking; Endoplasmic reticulum; Inositol-3 phosphate receptor

Mesh:

Substances:

Year:  2021        PMID: 34823105     DOI: 10.1016/j.ceca.2021.102504

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  1 in total

Review 1.  Cell Death Related Proteins Beyond Apoptosis in the CNS.

Authors:  Bazhena Bahatyrevich-Kharitonik; Rafael Medina-Guzman; Alicia Flores-Cortes; Marta García-Cruzado; Edel Kavanagh; Miguel Angel Burguillos
Journal:  Front Cell Dev Biol       Date:  2022-01-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.